Navigation Links
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Date:4/24/2009

nce the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, round-the-clock therapeutic drug levels; and to reduce side effects, including nausea, associated with high peak levels of exenatide exposure observed with injection administration. Unlike other extended delivery technologies such as polymers or albumin fusion, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required.

"We are very pleased with the rapid progress the Company has made with ITCA 650," said Alice Leung, President & CEO of Intarcia. "Our team has demonstrated the great potential for DUROS delivered therapies in advancing this important treatment candidate for type 2 diabetes patients from an idea to clinical stage development in 18 months."

ITCA 650 is the second DUROS delivery program Intarcia has moved into clinical development. In December 2008, Intarcia also completed enrollment of a phase 1b study for ITCA 638, which involves DUROS delivery of omega interferon for the treatment of chronic hepatitis C infection. "Many patients with type 2 diabetes are forced to manage dosing schedules and side effects of multiple drug therapies simultaneously to adequately control their disease," commented Ken Luskey, M.D., VP, Clinical Research at Intarcia. "We believe ITCA 650 will deliver improved glycemic control and provide a better tolerated, more convenient treatment option."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  MinuteClinic, the largest and fastest growing provider of retail ... opened its first walk-in clinics in the Corpus Christi ... Corpus Christi and Portland . A ... in December. The clinics are part of MinuteClinic,s national ... the Corpus Christi -area openings, there are now ...
(Date:10/2/2014)... 2, 2014  AxelaCare Health Solutions, www.axelacare.com , ... today that it has acquired Advanced Care, a ... provider.  Terms of the transaction were not disclosed. ... solutions pharmacies to 18 nationwide and expands AxelaCare,s national ... York - New Jersey metro ...
(Date:10/2/2014)... --  Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... Parsley , D.O. has joined the Company as its ... Dr. Parsley has been actively engaged with the Company ... He has served as Mast,s interim Chief Medical Officer ... Aires since April 2011.  Dr. Parsley previously was with ...
Breaking Medicine Technology:First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 2First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 3AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4
... Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ... development, assembly, marketing and sale of medical devices and ... will participate in the MEDICA 2010 International Trade Fair, ... Fairgrounds in Dusseldorf, Germany. More than ...
... 2010 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced that BioSpecifics, President, Tom Wegman, will ... Healthcare Conference on Wednesday, November 17, 2010, at 2:45 ... New York. A live webcast of the ...
Cached Medicine Technology:Dehaier Medical to Participate in MEDICA International Trade Fair 2Dehaier Medical to Participate in MEDICA International Trade Fair 3
(Date:10/2/2014)... Dennis Thompson HealthDay ... A newborn,s risk of developing celiac disease isn,t reduced by ... in wheat called gluten to an infant,s diet help prevent ... pair of new studies in the Oct. 2 New ... to rest hopes that a child could avoid celiac disease ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... - Scientists at the Toronto Western Research Institute (TWRI), ... the brain against the damaging effects of a stroke ... development for a few years. At this point, it ... drugs created to reduce the brain,s vulnerability to stroke ...
... sudden urge to urinate, affects the quality of life of ... respond to or can tolerate oral medications and may benefit ... of Rhode Island is conducting a study to compare the ... urge incontinence after trying other treatments. Patients are currently ...
... there,s hope. In the March 2012 print issue of ... the University of Florida report that a family of ... role in the regulation of skeletal muscle mass. Specifically, ... transcription factors prevents muscle wasting associated with cancer and ...
... , This release is available in French ... University of Montreal and CHUM Hospital,s International Health, will be ... be working on the funding of the fight against Noma. ... of children mostly in Sub-Saharan Africa. Despite the existence of ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Poor people ... more money are, a new study shows. This finding ... otherwise due to an "unconscious bias" they have against low-income ... Monterey Orthopaedic and Sports Medicine Institute in California, and colleagues. ...
... -- Researchers who used family trees dating back to ... inherited heart rhythm disorders say their findings can help ... with these disorders. Sudden cardiac death can occur ... Genetic testing can identify people with an inherited heart ...
Cached Medicine News:Health News:Canadian scientist develops world's most advanced drug to protect the brain after a stroke 2Health News:Women & Infants studying therapies to relieve urinary urge incontinence 2Health News:No workout? No worries: Scientists prevent muscle loss in mice, despite disease and inactivity 2Health News:Montrealer heads to Congo to fight childhood disfigurement 2Health News:Poor Patients Less Likely to Sue Doctors, Analysis Shows 2Health News:Family Tree May Aid Treatment of Inherited Heart Disorders 2
... cup system has been designed to enhance ... and cluster hole configurations. The objective of ... on three primary modes: Tilt, migration and ... result in initial and long-term fixation. The ...
Optimal solution for normal acetabulum and younger patients....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: